See more : Ludwig Enterprises, Inc. (LUDG) Income Statement Analysis – Financial Results
Complete financial analysis of Mangoceuticals, Inc. (MGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mangoceuticals, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Keppel REIT (KREVF) Income Statement Analysis – Financial Results
- Madhav Marbles and Granites Limited (MADHAV.NS) Income Statement Analysis – Financial Results
- Highland Transcend Partners I Corp. (HTPAF) Income Statement Analysis – Financial Results
- Naigai Tec Corporation (3374.T) Income Statement Analysis – Financial Results
- BankInvest Optima 10 Akk. KL (BIV10A.CO) Income Statement Analysis – Financial Results
Mangoceuticals, Inc. (MGRX)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.mangorx.com
About Mangoceuticals, Inc.
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Metric | 2023 | 2022 | 2021 |
---|---|---|---|
Revenue | 731.49K | 8.94K | 0.00 |
Cost of Revenue | 299.99K | 4.09K | 0.00 |
Gross Profit | 431.50K | 4.85K | 0.00 |
Gross Profit Ratio | 58.99% | 54.26% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 |
General & Administrative | 6.45M | 2.00M | 70.08K |
Selling & Marketing | 2.10M | 352.86K | -52.56K |
SG&A | 8.55M | 2.00M | 17.52K |
Other Expenses | 1.10M | 0.00 | 0.00 |
Operating Expenses | 9.65M | 2.00M | 17.52K |
Cost & Expenses | 9.95M | 2.00M | 17.52K |
Interest Income | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 6.47K | 181.00 |
Depreciation & Amortization | 24.89K | 3.86K | 70.08K |
EBITDA | -9.19M | -1.99M | 52.56K |
EBITDA Ratio | -1,256.00% | -22,236.48% | 0.00% |
Operating Income | -9.22M | -1.99M | -17.52K |
Operating Income Ratio | -1,260.28% | -22,279.70% | 0.00% |
Total Other Income/Expenses | 6.47K | -6.47K | -53.28K |
Income Before Tax | -9.21M | -2.00M | -17.70K |
Income Before Tax Ratio | -1,259.40% | -22,352.11% | 0.00% |
Income Tax Expense | 0.00 | -224.62K | -70.08K |
Net Income | -9.21M | -2.00M | -17.70K |
Net Income Ratio | -1,259.40% | -22,352.11% | 0.00% |
EPS | -6.45 | -0.12 | 0.00 |
EPS Diluted | -6.45 | -0.12 | 0.00 |
Weighted Avg Shares Out | 1.43M | 17.32M | 17.32M |
Weighted Avg Shares Out (Dil) | 1.43M | 17.32M | 17.32M |
Mangoceuticals stock extends pullback from previous session's intraday high
Mangoceutical stock jumps on heavy volume after Barstool Sports sponsorship deal
Best Penny Stocks To Buy Now? 4 Under $5 To Watch This Week
4 Penny Stocks To Buy According To Insiders This Quarter
How the Internet Turned Us Into Horrible Investors
5 Hot Penny Stocks To Watch With The Stock Market Down This Week
Trading Penny Stocks: Tips for Paying Taxes
MGRX Stock: What Is Going on With Mangoceuticals Today?
Top 4 Risk Off Stocks That Are Preparing To Pump This Month
Erectile dysfunction drugmaker Mangoceuticals fails to maintain IPO price
Source: https://incomestatements.info
Category: Stock Reports